- Why do some organisms retain the miraculous ability to repair and regenerate tissue?
- What are the genetic mechanisms that regulate tissue repair and regeneration in these organisms?
- Why have these genetic mechanisms, which are shared across species, been deactivated in humans and other mammals?
- How can we manipulate these genetic mechanisms with small molecule therapies to stimulate the repair and regeneration of tissues?
Novo Biosciences is a regenerative medicine company that is seeking to answer these and other fundamental questions about tissue repair and regeneration. Using animals that have retained the ability to repair and regenerate tissue as models, we are focused on the early-stage discovery of small molecule therapies to reactivate and stimulate the body’s natural repair mechanisms. We are targeting drug therapies that address muscle damage induced by heart attack and muscular dystrophy and nerve damage induced by cancer chemotherapy and diabetes.
Novo Biosciences’ unique approach uses animals that have retained the ability to repair and regenerate tissue to cost-effectively identify mechanisms of tissue repair and regeneration. This approach allows us to screen in vivo for drug therapies that trigger these mechanisms. We have identified three drug candidates that we are seeking to move into the clinical pipeline. As we move forward, we will continue to focus on discovering new lead molecules, leading them through Phase 1 clinical trials and forging partnerships to turn our discoveries into cures.
Novo Biosciences was founded in 2013 as a spin-off of the MDI Biological Laboratory, in Bar Harbor, Maine, an independent, non-profit biomedical research institution focused on research on aging and regenerative biology.